Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus CORTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus CORTRIL.
A-METHAPRED vs CORTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
None Documented
None Documented
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid